Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
3.
Ultraschall Med ; 17(1): 18-22, 1996 Feb.
Artículo en Alemán | MEDLINE | ID: mdl-8650516

RESUMEN

AIM: The relationship between tumour vessel density and tumour vitality in breast carcinoma has been well established in histopathological studies. Our objective was to find out if colour-coded sonography is helpful in the evaluation of suspicious breast masses. METHOD: 106 patients were studied; in all cases a biopsy was obtained. Peripheral and central blood vessels in a lesion were counted and peak systolic velocities (PSV) were measured as well as the resistive index (RI). The grade of vascularisation was scored on a scale from I-IV indicating an increasing vessel count and increasing PSV. RESULTS: 83% of the carcinoma (n = 61) and 45% of the benign lesions (n = 45) showed vascularity grade III or IV (hypervascularity). The mean PSV of all carcinomas was 0.23 m/s, in benign lesions 0.14 m/s (p < 0.005). Although G3 carcinomas showed higher vascularisation than G2 carcinomas, the difference was not statistically significant. T3 + 4 tumours had significantly higher PSV than T1 + 2 carcinomas (p < 0.01). In 12 of 23 cases with unclear morphology in the B-mode, the additional finding of hypervascularity led to the misinterpretation of a benign lesion as a carcinoma. CONCLUSION: Although increased vascularity correlated with degree of malignancy the finding of hypervascularity did not help to distinguish a benign from a malignant lesion in individual cases. Consequently, it did not help to reduce the biopsy rate. In benign lesions with hypervascularity and borderline morphology, the risk of a false positive diagnosis is high.


Asunto(s)
Neoplasias de la Mama/irrigación sanguínea , Neovascularización Patológica/diagnóstico por imagen , Ultrasonografía Doppler en Color , Adulto , Anciano , Anciano de 80 o más Años , Biopsia , Velocidad del Flujo Sanguíneo/fisiología , Mama/irrigación sanguínea , Mama/patología , Neoplasias de la Mama/patología , Capilares/diagnóstico por imagen , Capilares/patología , Diagnóstico Diferencial , Femenino , Humanos , Persona de Mediana Edad , Estadificación de Neoplasias , Neovascularización Patológica/patología , Resistencia Vascular/fisiología
4.
Eur J Clin Pharmacol ; 49(3): 215-20, 1995.
Artículo en Inglés | MEDLINE | ID: mdl-8665998

RESUMEN

We have investigated the disposition and plasma uric acid lowering effect of oxipurinol in ten healthy individuals following oral administration of three different formulations of oxipurinol and of allopurinol in equimolar doses. The reduction of plasma uric acid was clearcut up to 48 h. As estimated from plasma AUC0-infinity, Cmax, tmax, tlag, and urinary drug excretion, a conventional rapid release preparation of oxipurinol sodium was clearly superior to oxipurinol as free acid and to enteric coated microtablets of oxipurinol sodium. Plasma oxipurinol concentrations following a single dose of the conventional formulation of oxipurinol sodium were approximately 25% lower than those observed after an equimolar dose (300 mg) of allopurinol, but mean Cmax reached the value reported to be necessary for 90% inhibition of xanthine oxidase. Since prolonged administration will result in accumulation of oxipurinol because of its slow elimination, this type of oxipurinol formulation can be expected to meet the therapeutic requirements for a drug to lower plasma uric acid.


Asunto(s)
Alopurinol/farmacocinética , Inhibidores Enzimáticos/farmacocinética , Supresores de la Gota/farmacocinética , Oxipurinol/farmacocinética , Ácido Úrico/sangre , Administración Oral , Adulto , Alopurinol/administración & dosificación , Alopurinol/sangre , Alopurinol/química , Química Farmacéutica , Estudios Cruzados , Inhibidores Enzimáticos/administración & dosificación , Inhibidores Enzimáticos/sangre , Inhibidores Enzimáticos/química , Supresores de la Gota/administración & dosificación , Supresores de la Gota/sangre , Supresores de la Gota/química , Humanos , Masculino , Oxipurinol/administración & dosificación , Oxipurinol/sangre , Oxipurinol/química
5.
Arzneimittelforschung ; 43(10): 1072-5, 1993 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-8267672

RESUMEN

The uricostatic drug allopurinol (CAS 315-30-0) is used for treatment of hyperuricaemia and is mainly bio-transformed to the active metabolite oxipurinol (CAS 2465-59-0) in humans. A new assay was developed for the simultaneous determination of both compounds in plasma and urine using ultrafiltration and ion exchange purification steps for plasma and urine, respectively. Reversed-phase high-performance liquid chromatography with ultraviolet detection was applied for the separation and quantitation of both compounds. The limit of detection was 0.1 microgram/ml for both compounds in plasma and 0.2 and 0.5 microgram/ml for allopurinol and oxipurinol, respectively, in urine. Within-run and day-to-day precision of 3-5% and 5-7% was determined for plasma and 6-8% and 8-10% for urine analysis. The assays were further validated using liquid chromatography with photodiode array detection and by comparison with methods using protein precipitation as the purifying step. The high analytical recoveries, selectivity, sensitivity, accuracy and reproducibility were adequate for the measurement of both compounds in pharmacokinetic studies and for drug monitoring in patients on allopurinol therapy.


Asunto(s)
Alopurinol/análisis , Oxipurinol/análisis , Adulto , Alopurinol/sangre , Alopurinol/orina , Proteínas Sanguíneas/metabolismo , Cromatografía Líquida de Alta Presión , Cromatografía por Intercambio Iónico , Humanos , Masculino , Oxipurinol/sangre , Oxipurinol/orina , Espectrofotometría Ultravioleta , Ultrafiltración
6.
Rofo ; 158(5): 416-22, 1993 May.
Artículo en Alemán | MEDLINE | ID: mdl-8490149

RESUMEN

The MRT scans of 57 patients with Ewing or osteosarcomas and 34 patients with haematogenous osteomyelitis or periostitis/stress fractures were examined in order to determine whether a distinction between benign or malignant lesions is possible. Four criteria were evaluated: the margin of the bone marrow component; intensity and homogeneity of the T1 weighted signal in the bone marrow; presence of an extraosseous structured soft tissue mass and/or soft tissue edema. It was found that central osteosarcomas and Ewing's sarcomas reduced signal intensity of the marrow to become muscle-isointense with a well-defined margin. In acute haematogenous osteomyelitis and periostitis/stress fracture the marrow lesion was not sharply demarcated. In contrast to patients with bone sarcomas, only one case of osteomyelitis showed an extraosseous structured soft tissue mass. On the basis of these findings we believe that acute haematogenous osteomyelitis can be distinguished with high degree of accuracy from Ewing's sarcoma and central osteosarcomas.


Asunto(s)
Enfermedades Óseas/diagnóstico , Neoplasias Óseas/diagnóstico , Imagen por Resonancia Magnética , Sarcoma/diagnóstico , Adolescente , Adulto , Huesos/patología , Niño , Diagnóstico Diferencial , Femenino , Fracturas por Estrés/diagnóstico , Humanos , Pierna , Masculino , Osteomielitis/diagnóstico , Osteosarcoma/diagnóstico , Periostitis/diagnóstico , Sarcoma de Ewing/diagnóstico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA